NCT03223610 2026-04-20
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
National Institutes of Health Clinical Center (CC)
Genmab
Genmab
Acerta Pharma BV